The Important Role of Protein Kinases in the p53 Sestrin Signaling Pathway

被引:6
|
作者
Guelow, Karsten [1 ]
Tuemen, Deniz [1 ]
Kunst, Claudia [1 ]
机构
[1] Univ Hosp Regensburg, Dept Internal Med 1, Gastroenterol Hepatol Endocrinol Rheumatol & Infec, D-93053 Regensburg, Germany
关键词
p53; Sestrins; stress response; mTORC; nuclear factor erythroid 2-related factor 2 (Nrf2); mitophagy; autophagy; TUMOR-SUPPRESSOR; DNA-DAMAGE; GENE; AUTOPHAGY; ISOFORM; STRESS; TARGET; FAMILY; NRF2; DELTA-133P53-ALPHA;
D O I
10.3390/cancers15225390
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Cells experience various stress conditions, including replicative stress, oxidative stress, toxin-induced damage, and pathogen exposure. The tumor suppressor p53 initiates intricate cellular responses to mitigate such stress. Sestrins, induced by p53, play a pivotal role in these responses. The Sestrin family has three members, with Sestrin 2 being the most extensively studied. Here, all three Sestrins are considered, with a special focus on Sestrin 2. Sestrins trigger complex signaling cascades involving kinases and kinase complexes such as mTORC, AMP-activated kinase (AMPK), and Unc-51-like protein kinase 1 (ULK1). These kinase-driven responses enable cells to defend against cellular stress, facilitate repairs, and adapt to changing conditions, preventing damage accumulation in macromolecules such as nucleic acids, proteins, and lipids, and thereby averting malignant transformation. Thus, Sestrins essentially contribute to the prevention of cancer development. Because Sestrins also support adaptation to cellular stress and can thereby promote cell survival, these stress responses can also protect malignant tumor cells. Therefore, such anti-stress responses are a double-edged sword-on the one hand they prevent the onset of neoplasia, but on the other hand they can also shield an already established malignancy from the induction of cell death.Abstract p53, a crucial tumor suppressor and transcription factor, plays a central role in the maintenance of genomic stability and the orchestration of cellular responses such as apoptosis, cell cycle arrest, and DNA repair in the face of various stresses. Sestrins, a group of evolutionarily conserved proteins, serve as pivotal mediators connecting p53 to kinase-regulated anti-stress responses, with Sestrin 2 being the most extensively studied member of this protein family. These responses involve the downregulation of cell proliferation, adaptation to shifts in nutrient availability, enhancement of antioxidant defenses, promotion of autophagy/mitophagy, and the clearing of misfolded proteins. Inhibition of the mTORC1 complex by Sestrins reduces cellular proliferation, while Sestrin-dependent activation of AMP-activated kinase (AMPK) and mTORC2 supports metabolic adaptation. Furthermore, Sestrin-induced AMPK and Unc-51-like protein kinase 1 (ULK1) activation regulates autophagy/mitophagy, facilitating the removal of damaged organelles. Moreover, AMPK and ULK1 are involved in adaptation to changing metabolic conditions. ULK1 stabilizes nuclear factor erythroid 2-related factor 2 (Nrf2), thereby activating antioxidative defenses. An understanding of the intricate network involving p53, Sestrins, and kinases holds significant potential for targeted therapeutic interventions, particularly in pathologies like cancer, where the regulatory pathways governed by p53 are often disrupted.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Induction and activation of the p53 pathway: a role for the protein kinase CK2?
    Meek, David W.
    Cox, Miranda
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2011, 356 (1-2) : 133 - 138
  • [22] Induction and activation of the p53 pathway: a role for the protein kinase CK2?
    David W. Meek
    Miranda Cox
    Molecular and Cellular Biochemistry, 2011, 356 : 133 - 138
  • [23] Detection of the 113p53 protein isoform A p53-induced protein that feeds back on the p53 pathway to modulate the p53 response in zebrafish
    Guo, Lin
    Chua, Joy
    Vijayakumar, Danesh
    Lee, Kian Chung
    Lim, Kathy
    Eng, Huiyan
    Ghadessy, Farid
    Coomber, David
    Lane, David P.
    CELL CYCLE, 2010, 9 (10) : 1998 - 2007
  • [24] Chemotherapy mediates intestinal injury via p53/p53 upregulated modulator of apoptosis (PUMA) signaling pathway
    Zhan, Ya Shi
    Tan, Si Wei
    Mao, Wei
    Jiang, Jie
    Liu, Hui Ling
    Wu, Bin
    JOURNAL OF DIGESTIVE DISEASES, 2014, 15 (08) : 425 - 434
  • [25] DCAF13 inhibits the p53 signaling pathway by promoting p53 ubiquitination modification in lung adenocarcinoma
    Wei, Shan
    Xing, Jing
    Chen, Jia
    Chen, Liping
    Lv, Jiapei
    Chen, Xiaofei
    Li, Tang
    Yu, Tao
    Wang, Huaying
    Wang, Kai
    Yu, Wanjun
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [26] DCAF13 inhibits the p53 signaling pathway by promoting p53 ubiquitination modification in lung adenocarcinoma
    Shan Wei
    Jing Xing
    Jia Chen
    Liping Chen
    Jiapei Lv
    Xiaofei Chen
    Tang Li
    Tao Yu
    Huaying Wang
    Kai Wang
    Wanjun Yu
    Journal of Experimental & Clinical Cancer Research, 43
  • [27] The p53 Pathway in Glioblastoma
    Zhang, Ying
    Dube, Collin
    Gibert, Myron, Jr.
    Cruickshanks, Nichola
    Wang, Baomin
    Coughlan, Maeve
    Yang, Yanzhi
    Setiady, Initha
    Deveau, Ciana
    Saoud, Karim
    Grello, Cassandra
    Oxford, Madison
    Yuan, Fang
    Abounader, Roger
    CANCERS, 2018, 10 (09)
  • [28] Polyclonal antibody to porcine p53 protein: A new tool for studying the p53 pathway in a porcine model
    Qiu, Yafeng
    Shen, Yang
    Li, Xiangdong
    Liu, Qingwei
    Ma, Zhiyong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 377 (01) : 151 - 155
  • [29] 19q13.12 KRAB zinc-finger protein ZNF383 represses p53 signaling pathway by interacting with p53
    Liang, Yanying
    Zhang, Xiuyuan
    Geng, Wenwen
    Wang, Yun
    Ding, Yue
    Song, Qin
    Yuan, Yanzhi
    Zhao, Chunling
    Tian, Zhaoju
    Wang, Jian
    Tian, Chunyan
    CELLULAR SIGNALLING, 2022, 98
  • [30] Polymorphisms in the p53 pathway
    Pietsch, EC
    Humbey, O
    Murphy, ME
    ONCOGENE, 2006, 25 (11) : 1602 - 1611